Skip to main content
. 2014 Aug 5;15(1):84–94. doi: 10.1038/tpj.2014.34

Figure 3.

Figure 3

Steady-state plasma concentrations of endoxifen and metabolic ratio DM-Tam/(Z)-endoxifen in premenopausal breast cancer patients according to genotype-based CYP2D6 activity score: (a) Endoxifen concentrations in Singapore (upper panel, N=160, R2=0.38; P<10−12), Lebanon (middle panel, N=77, R2=0.34; P<10−4) and POSH (lower panel, N=306, R2=0.33; P<10−21) cohorts. (b) Metabolic ratios of DMT/(Z)-endoxifen in Singapore (upper panel, R2=0.46; P<10−17), Lebanon (middle panel, R2=0.55; P<10−9) and POSH (lower panel, R2=0.55; P<10−46) cohorts. (c) Metabolic ratio DM-Tam/(Z)-endoxifen across all cohorts (N=548, R2=0.53; P<10−77). Data are presented as boxplots with whiskers defined by 5th and 95th percentiles and extreme values outside the whiskers. DM-Tam, N-desmethyltamoxifen. **P<10−3; ***P<10−5; ****P<10−10. POSH, Prospective study of Outcomes in Sporadic versus Hereditary breast cancer.